Elite Pharmaceuticals (STU:ETF) Long-Term Capital Lease Obligation : €0.18 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Long-Term Capital Lease Obligation?

Elite Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.18 Mil.

Elite Pharmaceuticals's quarterly Long-Term Capital Lease Obligation stayed the same from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.18 Mil).

Elite Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Mar. 2021 (€0.03 Mil) to Mar. 2022 (€0.76 Mil) but then declined from Mar. 2022 (€0.76 Mil) to Mar. 2023 (€0.00 Mil).

Elite Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Elite Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Long-Term Capital Lease Obligation Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.15

0.03

0.76

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	0.18

Elite Pharmaceuticals (STU:ETF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Elite Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (STU:ETF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ELTP:USA

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines